Dan Levitan

I spoke with Christien Louviere of BDE Capital about his journey from a $330mm exit to becoming an independent sponsor. Christien shared excellent insights for folks looking to partner with business owners, rather than buy sellers out completely. Below are a few of the topics we covered: - Why he moved from “zero-to-one” startups to a buy-then-build strategy - How Christien's background shaped a focus on growth vs. cost-cutting - Why 20–40% rolled equity is central to his deal structures—and how it builds trust with sellers - Using scenario analysis with AI tools to evaluate management teams and uncover hidden key-person risks - How to identify when a $3–5M EBITDA company truly has a middle management layer—or is still founder-reliant For anyone investing in or buying small businesses, Christien’s approach provides a fresh lens on growth, alignment, and deal structuring. 🎥 Watch the full interview here → https://lnkd.in/ekfkaiej 🎧 Listen on Spotify: https://lnkd.in/e86Agx6V

33

8 Comments

💡Emerging GP Fundraising Insight #8: Rolling Closes Keep You Moving Small funds can't always afford to sit still until the target is hit. Rolling closes let you start deploying earlier, build a track record, and show momentum to prospective LPs. One GP told me that for Fund I ($5M target), he took capital as it came, signed, wired, and got to work. It wasn't perfect, but it kept the lights on and the deals moving. Sometimes the "sign and wire as it comes" approach is the only way to get moving. Takeaway: Momentum is a fundraising asset and rolling closes can help you keep it. Has anyone here used rolling closes as a strategic advantage?

29

13 Comments

🥾 #bootstrapping as a mindset should be ephemeral, one that requires a deliberate transition away from as a business enters sustained growth Appointing an established auditor is often regarded as a luxury and not part of bootstrapping Audits discipline a business - to be methodical, thorough and deliberate - traits that acquirers often seek in due diligence After all, "What gets inspected, gets respected," Anon We will share the traits of venture businesses sought and respected by MNC acquirers, join us if your business is out of the #bootstrapping mindset #fulfillingpotential #hepmil #oobmil

24

1 Comment

Huge step forward from the Dyad team. AI that actually clears the inbox and kills rekeying (not just talks about it): 📨 Email Triage Agent to route submissions automatically 📃 Extractor to pull data from PDFs straight into ALIS DX If you’re an MGA, wholesaler, or program administrator who wants teams focused on underwriting, not manual work, this is worth a look: https://hubs.la/Q03T_Q1S0

52

1 Comment

We invest at Pre-VC and Pre-Seed, and then help our founders find a Seed round when they're ready. Here are 27 Seed investors that we *know* are active right now. Blue Moon Bonfire Ventures Chingona Ventures Flying Fish Partners Foothill Ventures Great North Ventures ground game HealthX Ventures InsurTech Venture Partners KCRise Fund Las Olas Venture Capital Leva Capital Maven Ventures Monte Carlo Capital Moonshots Capital OneSixOne Ventures Oval Park Capital Pixel Perfect Ventures Range Ventures Revolution SNAK Venture Partners Startup Capital Ventures Supernode Global Susa Ventures Trilogy Equity Partners True Ventures True Wealth Ventures

77

15 Comments

Growth at all costs is out. Strategic expansion is in. One stat from our new report that says it all: By $100M ARR, 67% of growth comes from expansion, not net-new customers. We’re seeing a mindset shift among top-performing founders. They’re prioritizing customer success early, building in product-led growth loops, and measuring how they grow, not just how fast. Full analysis and benchmarks here: https://lnkd.in/gZruurYs #AI #SaaS #CustomerSuccess #BeyondBenchmarks

107

5 Comments

Every hire, product feature, and GTM experiment is a capital allocation decision, most teams just don’t call it that. I’m kicking off a 3-part series on capital allocation for founders, operators, and finance leaders with a simple question: ➡️ Will the next $1 you deploy become worth more than $1? Series overview Part 1: defines the core concept + the math Part 2: where capital goes + how to measure whether it’s working Part 3: AIMS framework for communicating allocation decisions to management teams and your board Part 1 (attached here) lays the practical foundation: 🔹 The $1 invested test and ROIIC vs. hurdle rates (scoreboard vs. decision lens) 🔹 A lightweight “investment brief” to evaluate bets (GROW / BUILD / BUY) 🔹 The small metric toolkit that translates finance into operating decisions (NPV / payback / ROIIC / incremental margin) 🔹 Early-stage proxies when DCF inputs are unknowable (burn multiple + revenue quality) 🔹 Operator “vital signs” to spot drift early (profit engine, leverage, cash conversion, optics) Series Roadmap ✔️ This series (Parts 1–3): breadth-first. shared, lightweight framework to define value creation, choose decision-grade metrics, and communicate tradeoffs clearly ✔️ Next series: depth-first. momentum drivers + operational decisions that need near real-time measurement to spot drift early and course-correct fast Read Part 1 here and Part 2 and 3 on substack. Next Series will be out next week. 💰 What’s one bet you’re funding right now, and how will you prove it’s working?

6

Excited to announce that Esplanade Ventures has co-led a Seed round investment in No Barrier Medical Translation, joined by our valued partners Nadav Shimoni, M.D.  at A-Squared Ventures, and Bill Evans and Sean Day from Rock Health Capital. As an immigrant who has faced language barriers firsthand, I was immediately inspired when I met Eyal Heldenberg. His authenticity and deep expertise in voice AI, combined with a nuanced understanding of the complexities in medical translation, are truly compelling. I am proud to support No Barrier’s mission to provide secure, accessible, and HIPAA-compliant medical interpretation services—transforming healthcare access for tens of millions of Americans and Canadians who have been historically underserved due to language barriers. No Barrier’s AI-powered medical interpreter offers real-time, clinically accurate, and privacy-first interpretation tailored specifically for healthcare environments. This innovation is a significant leap toward equitable healthcare by empowering limited English proficiency (LEP) populations with timely, reliable, and culturally sensitive communication at every stage of care. #DigitalHealth #VoiceAI #HealthTech #Founders #VentureCapital #NoBarrier

58

3 Comments